Oculomedica Sp. z o.o.

Bydgoszcz 15 trials 5 recruiting

15 Registered trials

5 Currently recruiting

Organisation

Oculomedica Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100044752

Address

Ul. Ogrody 14, 85-870, Poland

Departments

2205: Ophthalmology
N/A
NA
NAP
Oculomedica Sp. z o.o.
Ophtalmology
Ophthalmology
Specjalistyczny Ośrodek Okulistyczny Oculomedica

Clinical trials at this site (15)

Search interface

A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8… Recruiting

2025-524575-22-00 Neovascular age-related macular degeneration (NVAMD) 10 2026-06-30
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME Recruiting

2025-523937-25-00 Diabetic Macular Edema (DME) 5 2026-05-06
Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting

2024-513174-22-00 Atrophic Age-related Macular Degeneration (AMD) 4 2026-04-14
A study to test whether BI 1815368 helps people with an eye condition called diabetic macular edema Recruiting

2024-520384-14-00 Centre-involved diabetic macular edema 4 2025-11-20
Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting

2024-516924-32-00 Neovascular Age-Related Macular Degeneration (nAMD) 5 2025-10-17
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended

2025-520809-12-00 Diabetic Macular Edema 10 2025-10-16
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended

2024-510944-30-00 Diabetic Macular Edema 10 2024-11-22
A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended

2023-507563-19-00 Thyroid eye disease 5 2024-11-05
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended

2023-507217-10-00 Thyroid eye disease 5 2024-04-12
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503669-50-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-12-27
A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended

2022-502174-16-00 Macular edema secondary to retinal vein occlusion 5 2023-09-13
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended

2024-512945-18-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2021-11-30
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended

2024-512880-30-00 Neovascular Age-related Macular Degeneration (wet AMD) 5 2021-08-27
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio… Ended

2023-509206-29-00 Neovascular age-related macular degeneration (nAMD) 5